Carfilzomib’s Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records

Carfilzomib is a promising anticancer drug for relapsed/refractory multiple myeloma (RRMM). However, real-world evidence has only investigated the cardiovascular safety of carfilzomib, and there is a high demand for thorough safety evaluations. We aimed to comprehensively evaluate the risk of advers...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Ha Young, Lee, Hyun Kyung, Kim, Chae Jeong, Yoon, Sung-Soo, Kim, In-Wha, Oh, Jung Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603615/
https://www.ncbi.nlm.nih.gov/pubmed/36294140
http://dx.doi.org/10.3390/ijerph192013560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603615/
https://www.ncbi.nlm.nih.gov/pubmed/36294140
http://dx.doi.org/10.3390/ijerph192013560

Ejemplares similares